A Phase 1/2 study of filanesib alone and in combination with low-dose dexamethasone in relapsed/refractory multiple myeloma

BACKGROUND: Filanesib (ARRY-520) is a highly selective inhibitor of kinesin spindle protein, which has shown preclinical anti-myeloma activity. METHODS: This open-label Phase 1/2 study determined the maximum tolerated dose (MTD) of filanesib administered on Days 1 and 2 of 14-day cycles in patients...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancer
Egile Nagusiak: Shah, Jatin J., Kaufman, Jonathan L., Zonder, Jeffrey A., Cohen, Adam D., Bensinger, William I., Hilder, Brandi, Rush, Selena, Walker, Duncan, Tunquist, Brian, Litwiler, Kevin, Ptaszynski, Mieke, Orlowski, Robert Z., Lonial, Sagar
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2017
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5856158/
https://ncbi.nlm.nih.gov/pubmed/28817190
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30892
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak